I obtained my Ph.D. in Hematology-Oncology at the Saint-Louis Hospital in Paris. My graduate studies revealed an alternative p53 pathway in the endoplasmic reticulum stress response. This involved a p53-mediated suppression of p21 and subsequent sensitization of cancer cells to DNA damage-induced apoptosis, highlighting conditions that may be manipulated to potentiate the cytotoxicity of existing anticancer drugs.
I joined Dr. Ari Melnick's lab with the desire to perform cancer research that can translate into innovative targeted therapy. Recurrent mutations were recently found by others and us in patients with follicular lymphoma (FL) and diffuse large B cell lymphoma (DLBCL). These lymphomas develop from germinal center B cells, which are highly proliferative and undergo somatic hypermutation before differentiating into antibody-producing cells. I am studying how these mutations impact on normal B cell development to favor lymphomagenesis.